These Analysts Increase Their Forecasts On Arvinas After Q1 Results - Arvinas (NASDAQ:ARVN), Pfizer (NYSE

Benzinga
Open on Benzinga

Arvinas Inc (NASDAQ: ARVN ) reported downbeat results for the first quarter on Tuesday .

The company posted quarterly losses of 90 cents per share which missed the analyst consensus estimate of losses of 87 cents per share. The company reported quarterly sales of $15.600 million which missed the analyst consensus estimate of $18.097 million.

Arvinas shares rose 1.7% to trade at $9.74 on Wednesday.

These analysts made changes to their price targets on Arvinas following earnings announcement.

BTIG analyst Jeet Mukherjee maintained Arvinas with a Buy and raised the price target from $16 to $18. Barclays analyst Etzer Darout maintained the stock with an Overweight rating and raised the price target from $18 to $20.

Considering buying ARVN stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here .


Posted In: Earnings News Price Target Markets Analyst Ratings Trading Ideas PT Changes